Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Therapeutic Area Partnerships Features Next Generation of Oncology Treatments
New Wave of Newer Classes Will Be Discussed by Experts at Campbell Alliance

BRIDGEWATER, NJ -- (Marketwire) -- 11/19/12 -- Next week Elsevier Business Intelligence will host the 7th Annual Therapeutic Area Partnerships (TAP) at The Westin Copley Place in Boston on Nov. 28-30, 2012. TAP is the most efficient partnering meeting for biopharmaceutical companies and executives seeking to understand, within their therapeutic area portfolio, the strategic outlook for new products in development, alliance opportunities, and current industry pipeline needs and future projections.

One of the six therapeutic areas featured at the conference, oncology remains by far the largest and most active deal-making space in the biopharmaceutical industry. While many new drugs will reach the market in the next few years, existing blockbusters and other widely used agents will soon go generic, potentially impacting reimbursement and uptake for novel medications. Emerging diagnostic biomarkers, immunotherapies and conjugated biological therapies have the potential to transform the way patients are treated. The fast-changing oncology landscape and its implications for the industry will be the subject of a roundtable of oncology business development leaders from four major global pharmaceutical firms guided by an expert team from Campbell Alliance, an industry leader in biopharmaceutical and medical technology consulting and part of inVentiv Health.

The oncology-specific segments of TAP include a panel discussion and presentation of the Top Projects to Watch. The panel, including executives from AstraZeneca, Genentech, EMD Serono and Sanofi, will give attendees actionable intelligence on the trends, hurdles and opportunities that will shape the future of oncology drug development, alliances, and commercialization.

The Top Projects to Watch in oncology were hand-picked by the Campbell Alliance team based on their likelihood of success as future products. The companies confirmed to present their oncology projects this year are:

Apogenix GmbH: (Apocept) APG101
BIND Biosciences: BIND-014
Ceres Oncology: VGX-100
Jennerex Biotherapeutics: JX-929
KaloBios Pharmaceuticals, Inc.: KB004
Macrogenics: MGAH22
MEI Pharma: ME-344
EnGeneIC: EDV technology
Shape Pharmaceuticals: SHP 141
Cerulean: CRLX101

"The next decade in oncology will see newer classes of agents added to the treatment armamentarium," said Guru Muralimohan, engagement manager at Campbell Alliance. "Cytotoxics will become smarter and more targeted. Immunotherapies will produce a new wave of blockbusters as they leverage the human body's own immune system to help combat cancer. And, next generation agents targeting cancer cell metabolism will have the potential for disruptive change in the oncology treatment paradigm."

"These ten assets represent the leading edge of this sea change in oncology, and were chosen through an exhaustive process that took into account a variety of factors," added Jonathan Betts, Engagement Manager at Campbell Alliance. Such factors included what key opinion leaders have defined as the most promising mechanistic approaches and emerging trends based on Campbell Alliance's 2012 Dealmakers' Intentions Survey as well as the firm's understanding of areas of high current licensing activity within oncology and knowledge gained through assisting multiple companies develop oncology strategies.

Both Muralimohan and Betts will co-present the oncology Top Projects to Watch.

TAP is a one-of-a-kind opportunity to assess some of the most promising drugs in development and available for partnering in Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious Diseases, Autoimmune/Anti-Inflammatory Diseases, and Hot Space. Attracting the highest concentration of senior-level biotechnology and pharmaceuticals executives, TAP has come to be regarded as one the most productive, results-oriented deal-making conferences in the industry. For more information, or to register for this event, visit www.tapartnerships.com.

About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media contact:
Mike Fergus
Elsevier Business Intelligence
908-547-2167
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Internet of @ThingsExpo Silicon Valley announced today its first 20 all-star speakers and sessions for its upcoming event, which will take place November 4-6, 2014, at the Santa Clara Convention Center in Silicon Valley. @ThingsExpo, the first and largest IoT event in the world, debute...
Everything from jet engines to refrigerators is joining the Internet of Things, pushing networks to the brink. In a new Boeing 747, almost every part of the plane is connected to the Internet, recording and, in some cases, sending continuous streams of data about its status. General El...
The IoT has the potential to transform the world, bringing new functions and efficiency to big problems such as disease, poverty, traffic, and government transparence. It also makes for a nice Christmas gift for “kids in science fair projects.” This latter point was made by Broadcom an...
The Internet of Things (IoT) is getting personal. Wearables, ingestables, even implantables – devices that not only help us with our fitness, but can monitor and manage disease and its treatment – are right around the corner. And where the IoT goes, money follows. In this case, Big Pha...
Such devices and connected technologies exist today, and the sector is driving the leading edge of the Internet of Things under the label of the “Connected Home” or “Smart Home”. Fact is, some pretty traditional low-tech concepts are becoming technology-enabled, such as/including locki...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE